Jefferies Lifts Numbers on Regeneron Pharma (REGN)

Jefferies boosted estimates and its price target on Regeneron Pharma (NASDAQ: REGN) from $127 to $163 while reiterating its Buy rating.

The firm comments, "With Eylea sales outperforming by a wide margin yet again, REGN hikes its FY12 U.S. Eylea sales again to $500-$550M, sig higher than our $314M and cons $318M. Given continued strong Eylea sales supporting a highly favorable outlook in add’l indications and ex-U.S. mkts, we raised our PT to $163 (from $127) on increased penetration across wAMD, CRVO and DME globally."

The firm raised Q1 EPS ($0.12) to $0.19, FY from ($0.36) to $0.38 and FY13 from $1.79 to $3.13.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $138.60 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
• Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer